Markets, capital, and the discipline of patient investing.
RFC Capital Research publishes the independent analysis of Ruslan Averin — an investor focused on public markets, sovereign and corporate fixed income, cross-border real estate, and capital allocation across emerging and frontier markets.
No institutional mandate, no house view to defend — a working record of how one investor thinks about risk, value, and the markets most analysts avoid.
Texas Politics Versus Nuclear Contracts: What CEG and NRG Must Show on 9 November
Constellation Energy and NRG Q3 2026 earnings preview: Zacks expects $3.90 and $3.44 a share after the Texas vote sent NRG down 13.5% in a day.
MarketsSix Healthcare Beats, Three Verdicts: Why CVS Fell While McKesson and Humana Gained
CVS Q3 2026 results beat Zacks at $2.09 a share, yet the breakup plan sent the stock down 12.53%; McKesson, Cardinal and Humana raised guidance.
MarketsMidterms 2026: a Democratic Congress, a data-centre scare and a jobs beat move markets
2026 midterm election results and markets: the S&P 500 lost 2.68% in the week as a data-centre scare hit AI stocks and 165,000 jobs lifted hike odds.
MarketsCVS Health Q3 2026 preview: Aetna's cost ratio matters more than the $1.62 EPS estimate
CVS Health Q3 2026 earnings preview: consensus EPS $1.62, Aetna MBR seen at 92.4%, 2026 guide $7.90–8.10 and the 2027 floor of $8.44 in focus.
MarketsMarvell's $115 billion Lumentum bet: how an all-stock premium turned into a discount
Marvell Lumentum deal: $115 billion all-stock offer, MRVL down 12.72%, LITE down 18.59%, SOX down 3.37%. Terms, spread, valuation, regulatory risk.
MarketsCencora by Morning, McKesson by Evening: The 4 November Test for US Drug Wholesalers
McKesson and Cencora earnings preview: Zacks sees EPS of $10.69 and $4.56 on 4 November; fiscal 2027 guidance, GLP-1 growth and MFN risk in focus.